COMPANY PROFILE

Deep Genomics

Explore full profile

Deep Genomics is using artificial intelligence to build a new universe of life-saving genetic therapies

Toronto, CanadaFounded 2014Biotech & Life Sciences

Valuation $500M–1B Last recorded · 2021

Headcount 100–500 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Deep Genomics

Deep Genomics is a pioneering startup operating in the biotechnology sector, specifically in the field of drug development. The company uses artificial intelligence (AI) to unravel the complexities of RNA biology and identify potential therapeutic candidates for a range of genetic conditions. Its primary offering is the AI Workbench, a proprietary tool that uses data-driven prediction to identify novel targets for drug development.

Read full description

Deep Genomics serves a broad range of clients, including pharmaceutical companies, research institutions, and healthcare providers. The company operates in the rapidly growing market of AI-driven drug discovery, which is expected to revolutionize the pharmaceutical industry.

The business model of Deep Genomics is based on the development and licensing of its AI Workbench. The company generates revenue by identifying leads for novel drug targets and developing potential therapies. These are then either pursued internally or licensed to partners for further development and commercialization.

In 2018, the company's AI Workbench identified its first targets where RNA splicing was the defect. The updated version, AI Workbench 2.0, released in 2020, expanded the number of mechanisms for increased expression. The company is currently developing AI Workbench 3.0, which will further increase the number of mechanisms and genetic variants it can target, including more complex genetic diseases.

In summary, Deep Genomics is a cutting-edge biotech startup that uses AI to accelerate drug discovery and development. Its innovative approach has the potential to transform the pharmaceutical industry and improve treatment options for patients with genetic conditions.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2014
Headquarters: Toronto, Canada
Employees: 110
Open positions: 4
Dealroom signal: 90.3/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Testing, Analytics, Biotechnology, Drug Development, DNA, Vaccines
Technology: Artificial Intelligence, Deep Tech, Machine Learning
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

6 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES COther financing	Jul 2021	$180M	$720M	Khosla Ventures · Alexandria Venture Investments · Amplitude Ventures · Magnetic Ventures	↗
SERIES BOther financing	Jan 2020	$40M	$160M	True Ventures · Khosla Ventures · Future Ventures · Magnetic Ventures	↗

Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Deep Genomics website traffic

Latest recorded traffic for Deep Genomics is 8.2K monthly website visits, down 25.5% over the last three months. Deep Genomics's team grew 10% over the past year.

Latest monthly visits8.2K 3-month web change-25.5% 1-year team growth+10%

Monthly website visitsApr 2016–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Senior Scientist, Analytical ChemistryCambridge, MA · Other · Sep 3, 2026 Principal Research AssociateCambridge, Massachusetts, United States, Northern America, Americas · Other · Aug 1, 2026 Senior Research Scientist, Machine Learning (BioFM)Toronto, Ontario, Canada, Northern America, Americas · Data Science & Engineering · Jun 20, 2026

3 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
CDC4X DiscoveryC4X Discovery - building the world's most productive drug discovery engine	Manchester, United Kingdom	Operational	16	$20M	$14M
FGFabric GenomicsGlobal healthcare platform for genomic data analysis - Formerly Omicia	San Francisco, United States	Acquired
IMInSilico MedicineDevelops an AI platform for drug development to treat cancer and age-related diseases	Cambridge, United States	Operational
CHChemifyDigitizing chemistry by developing technology to convert chemical code into molecules and vice versa	Glasgow, United Kingdom	Operational
NTNucleome TherapeuticsDecoding the dark matter of the human genome to discover first-in-class precision medicine	Oxford, United Kingdom	Operational
ETEmedgene technologiesEmedgene uses AI to automatically interpret genetic tests, so that health organizations can scale personalized care to wider populations	Palo Alto, United States	Acquired
RPRecursion PharmaA clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering to industrialize drug discovery	Salt Lake City, United States	Operational
DSDeep Trait S.A.Biotechnology company with a mission to address fundamental questions of food supply, health care and life itself with artificial intelligence	Aschersleben, Germany	Operational